QIAGEN reports results for fourth quarter and full-year 2019
Delivers on Q4 2019 net sales outlook, exceeds on adjusted EPS Net sales of $413.5 million (+3% actual, +4% CER, vs. ~+3% CER outlook) Diluted EPS $0.19; adjusted EPS $0.48 ($0.48 CER, +20% CER vs. ~$0.45-0.46 CER outlook) Adjusted operating income margin rises to 33.5% of sales vs. 29.6% in Q4 2018 Achieves FY 2019... Read more